BioAge Labs said on Friday it is discontinuing its mid-stage trial studying its experimental drug as a monotherapy and in combination with Eli Lilly’s tirzepatide for the treatment of obesity. The drug developer decided to stop the trial after liver transaminitis, or high levels of certain liver enzymes, were observed in patients receiving the experimental drug, azelaprag. Tirzepatide is the active ingredient in Lilly’s diabetes drug Mounjaro and weight-loss treatment Zepbound. The mid-stage trial enrolled about 220 individuals with obesity aged 55 years and older.
BioAge discontinues mid-stage trial of obesity drug
